ARQT PEER ANALYSIS

Arcutis Biotherapeutics Inc — metric-by-metric comparison with peers and the industry median

ARQTArcutis Biotherapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

ARQTIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	ARQT	TLX	MSB	CSL	Ind. Median
P/E	—	—	—	30.04	18.00
P/B	19.44	6.26	—	2.25●	3.60
EV/EBITDA	231.31	118.24	—	10.37●	15.20
P/S	8.87	3.18	30.99	2.67●	10.43

Financial Health
Metric	ARQT	TLX	MSB	CSL	Ind. Median
Current Ratio	2.68●	1.43	—	2.57	5.90
Debt/Equity	7.0%●	112.3%	—	67.4%	10.9%
NetDebt/EBITDA	-14.03●	13.13	—	2.22	1.15

Profitability
Metric	ARQT	TLX	MSB	CSL	Ind. Median
Net Margin	-0.6%	-0.9%	-115.3%	9.2%●	-125.7%
ROE	-1.4%	-1.8%	-11.3%	7.7%●	-47.5%
ROA	-0.6%	-0.7%	-8.6%	3.8%●	-35.8%
EBITDA Margin	3.6%	3.0%	-76.6%	32.8%●	-105.8%

Growth + Dividend
Metric	ARQT	TLX	MSB	CSL	Ind. Median
Rev. Growth	95.3%	56.3%	410.4%●	4.8%	5.1%
NI Growth	—	—	—	-39.4%	12.1%
Div. Yield	—	—	0.0%	2.5%●	0.2%
Payout	—	—	0.0%	103.1%	0.0%

Valuation
Metric	ARQT	IDYA	RLAY	RARE	ELVN	BEAM	Ind. Median
P/E	—	—	—	—	—	—	18.00
P/B	19.44	3.59	5.50	-14.78●	7.04	3.27	3.60
EV/EBITDA	231.31	—	—	—	—	—	15.20
P/S	8.87	14.95	330.66	5.21●	—	23.22	10.43

Financial Health
Metric	ARQT	IDYA	RLAY	RARE	ELVN	BEAM	Ind. Median
Current Ratio	2.68	10.74	22.13	2.02	40.32●	16.99	5.90
Debt/Equity	7.0%	3.1%	4.9%	-508.5%●	0.1%	21.5%	10.9%
NetDebt/EBITDA	-14.03●	4.74	2.23	-1.56	4.59	30.00	1.15

Profitability
Metric	ARQT	IDYA	RLAY	RARE	ELVN	BEAM	Ind. Median
Net Margin	-0.6%●	-62.2%	-2,554.1%	-91.0%	—	-39.7%	-125.7%
ROE	-1.4%●	-14.3%	-40.0%	—	-26.6%	-5.7%	-47.5%
ROA	-0.6%●	-13.1%	-36.4%	-46.7%	-25.7%	-4.4%	-35.8%
EBITDA Margin	3.6%●	-60.1%	-2,560.7%	-75.2%	—	-19.5%	-105.8%

Growth + Dividend
Metric	ARQT	IDYA	RLAY	RARE	ELVN	BEAM	Ind. Median
Rev. Growth	95.3%	3,118.1%●	39.0%	13.3%	-100.0%	158.0%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on ARQT

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 8, 26. This content is for informational purposes only and is not investment advice.